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Abstract 
Objective  
To quantify variability of insulin requirements during closed-loop insulin delivery. 
 
Research Design and Methods  
We retrospectively analyzed overnight, daytime and total daily insulin amounts 
delivered during multicenter closed-loop trial involving 32 adults with type 1 diabetes. 
Participants applied hybrid day-and-night closed-loop under free-living home 
conditions over 12 weeks. The coefficient of variation was adopted to measure 
variability of insulin requirements in individual subjects.   
 
Results 
Data were analyzed from 1,918 nights, 1,883 daytime periods and 1,564 total days 
characterized by closed-loop use over 85% of time. Variability of overnight insulin 
requirements [coefficient of variation 31%(4), mean(SD)] was nearly twice as high as 
variability of total daily requirements [17%(3),p<0.001] and was also higher than 
variability of daytime insulin requirements  [22%(4), p<0.001]. 
 
Conclusions 
Overnight insulin requirements were significantly more variable than daytime and 
total daily amounts. This may explain why some people with type 1 diabetes report 
frustrating variability in morning glycemia. 
INTRODUCTION 
Closed-loop insulin delivery is an emerging treatment modality for people with type 1 
diabetes (1). Multi-week free-living overnight or day-and-night home investigations 
demonstrated improved glycemic control and reduced hypoglycemia with hybrid 
closed-loop compared to conventional sensor-augmented pump therapy (2-4). 
Insulin delivery modulated by closed-loop systems reflects the amount of insulin 
required in real-time which may vary from night-to-night and from day-to-day. The 
present investigation measures night-to-night and day-to-day variability of insulin 
requirements in adults with type 1 diabetes over 12 weeks of closed loop insulin 
delivery (2).  
RESEARCH DESIGN AND METHODS 
We retrospectively analyzed overnight (23:00 to 07:00), daytime (07:00 to 23:00) and 
total daily (midnight to midnight) insulin delivery during closed-loop period in a 
multicenter (United Kingdom, Germany and Austria), randomized cross-over study 
involving 32 subjects with type 1 diabetes and conducted in free-living home settings 
(2). Subjects underwent 4 to 6 weeks optimization of insulin pump therapy using 
real-time continuous glucose monitoring with trained pump educators before 
randomization. Day-and-night closed-loop insulin delivery was then applied over 12 
weeks using a hybrid approach, in which participants additionally administered 
prandial insulin using the standard bolus wizard.   
 
We calculated relative overnight, relative daytime and relative total daily insulin 
requirements defined as the percentage of the total amount of insulin administered 
by closed-loop during the relevant time period, over the optimized insulin pump 
amounts determined prior to the start of closed-loop period (Calculating variability of 
insulin requirements, Supplemental Appendix). For each subject, an individual 
coefficient of variation of overnight, daytime and total daily insulin requirements over 
12 weeks was calculated to represent variability of insulin requirements. A repeated 
measures least-square regression model was used to contrast variability (the 
coefficient of variation) of overnight, daytime and total daily requirements. Post-hoc 
analysis using Tukey test was used for pairwise comparisons. A linear mixed-effect 
regression analysis was used to relate the individual coefficient of variation of insulin 
requirements (dependent variable) and subjects’ baseline characteristics 
(independent predictors: gender, age, BMI, duration of diabetes, duration of pump 
use and HbA1c at the start of closed-loop use). Statistical analyses were performed 
using SPSS, version 21 (IBM Software, Hampshire, U.K.). Data are reported as 
mean(standard deviation) unless stated otherwise. P values less than 0.05 were 
considered statistically significant.  
RESULTS 
We analyzed data from 1,918 nights, 1,883 daytime periods and 1,564 total days 
characterized by closed-loop use over 85% of time in 32 adults [male/female 17/15, 
age 39.9(9.5) years, BMI 25.4(4.4) kg/m2, duration of diabetes 21.2(9.3) years, 
duration of pump use 7.9(6.0) years, HbA1c at the start of closed loop use 7.6%(0.8),   
60(9) mmol/mol, HbA1c at the end of closed loop use 7.3%(0.8), 56(9) mmol/mol]. 
Figure 1 shows individual overnight, daytime and total daily insulin requirements 
ranging from approximately 50 to 300%, 50 to 200% and 70 to 200%, respectively, 
relative to baseline requirements. The coefficients of variation differed between the 
three periods (p<0.001). Overnight insulin requirements were 14 percentage points 
higher than the coefficient variation of total daily requirements [31%(4) vs. 17%(3), 
p<0.001] and 9 percentage points higher than daytime requirements [31%(4) vs. 
22%(4), p<0.001] (Supplemental Figure S1). Supplemental Table S1 reports the 
regression coefficients of baseline predictors in the mixed-effect regression analyses. 
The coefficient of variation of overnight insulin requirements in male subjects was 
3.7% higher than in females (p=0.03). No other relationship was observed. 
CONCLUSIONS 
To our knowledge, this is the first study to report on the variability of overnight, 
daytime and total daily insulin requirements over a prolonged period in adults with 
type 1 diabetes.  We report highly variable overnight insulin requirements (from half 
to three-fold of the baseline amounts) and to a lesser extent during daytime and over 
24 hours (from half to two-fold of the baseline amounts) over 12 weeks of free-living 
home use of closed-loop insulin delivery.  
 
Potential factors contributing to variability of overnight insulin requirements include 
the composition of evening meal (5), the prolonged effect of daytime exercise on 
glucose turnover (6), variable insulin absorption (7) encompassing the effect of 
infusion set change (8) and lipohypertrophy (9), and changes in insulin sensitivity 
induced by stress, intercurrent illness (10) and menstrual cycle phases in women 
(11). We observed mean overnight insulin requirements 31% higher than baseline 
optimized insulin dose (data not shown), despite  weekly continuous-glucose-
monitoring guided optimization of insulin pump settings  by experienced healthcare 
professionals.  Concerns related to hypoglycemia especially overnight (12) may have 
limited further insulin therapy intensification underscoring the need for closed-loop 
insulin delivery when insulin requirements are highly variable.  
 
Predictors of variability of insulin requirements may support clinical management and 
inform treatment goals. The regression analysis demonstrated a potential gender 
cofactor with a surprisingly greater overnight variability observed in male compared 
to female participants despite a documented effect of menstrual cycle phases in 
women (11).The notable gender differences is unexpected and warrant further 
investigations to exclude the possibility of chance finding.  
 
During the past decade, clinical trials of closed-loop insulin delivery have transitioned 
from controlled settings in research facilities to free-living home conditions with 
improvements demonstrated in time spent in the target glycemic range, mean 
glucose as well as reduced hypoglycemia (2-4). This was achieved despite or more 
appropriately because of variable overnight and total daily insulin requirements, as 
reported in the present study. Closed-loop systems with adaptive control algorithms 
have the advantage of autonomously and continually assessing insulin requirements 
addressing the unmet need of managing day-to-day and within-day variability 
commonly observed in clinical practice. The present analysis pinpoints the reasons 
why people with type 1 diabetes benefit from closed-loop insulin delivery and 
indicates that greatest benefit may apply overnight when insulin requirements are 
most variable and real-time adaptive insulin delivery is most desirable.  
 
The main strength of the present study is the quantification of variability of insulin 
requirements derived from data collected over prolonged period under free-living 
conditions reflecting participants’ insulin needs in real-life. Factors leading to night-
to-night and day-to-day differences in insulin requirements are still not fully 
understood. Potential predictors such as the daily level and types of physical 
activities (13) and meal composition were not available, which is a limitation of the 
present analyses.  
 
In conclusion, insulin requirements assessed by closed loop insulin delivery during 
the overnight period were significantly more variable than daytime and total daily 
amounts. This may explain why some people with type 1 diabetes report frustrating 
variability in morning glycemia.   
Figure 1. Insulin requirements relative to baseline amounts during closed-loop 
insulin delivery. Each box plot represents individual insulin requirements over 
12 weeks of closed-loop insulin delivery (black box plots: overnight (23:00 to 
07:00); grey box plots: daytime (07:00 to 23:00); white box plots: midnight-to-
midnight) relative to insulin delivery prior to initiating closed loop (N=32). The 
coefficients of variation of overnight, daytime and total daily insulin 
requirements are 31%(4) vs. 22%(4) vs. 17%(3) (p < 0.001 for pairwise 
comparisons between any two time periods). 
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